Targeting TrkB with a Brain-Derived Neurotrophic Factor Mimetic Promotes Myelin Repair in the Brain

J Neurosci. 2018 Aug 8;38(32):7088-7099. doi: 10.1523/JNEUROSCI.0487-18.2018. Epub 2018 Jul 5.

Abstract

Methods to promote myelin regeneration in response to central myelin loss are essential to prevent the progression of clinical disability in demyelinating diseases. The neurotrophin brain-derived neurotrophic factor (BDNF) is known to promote myelination during development via oligodendrocyte expressed TrkB receptors. Here, we use a structural mimetic of BDNF to promote myelin regeneration in a preclinical mouse model of central demyelination. In female mice, we show that selective targeting of TrkB with the BDNF-mimetic enhances remyelination, increasing oligodendrocyte differentiation, the frequency of myelinated axons, and myelin sheath thickness after a demyelinating insult. Treatment with exogenous BDNF exerted an attenuated effect, increasing myelin sheath thickness only. Further, following conditional deletion of TrkB from premyelinating oligodendrocytes, we show the effects of the BDNF-mimetic on oligodendrocyte differentiation and remyelination are lost, indicating these are dependent on oligodendrocyte expression of TrkB. Overall, these studies demonstrate that targeting oligodendrocyte TrkB promotes in vivo remyelination in the brain.SIGNIFICANCE STATEMENT Novel strategies to promote myelin regeneration are required to prevent progressive neurodegeneration and clinical disability in patients with central demyelinating disease. Here, we test whether selectively targeting the TrkB receptor on the myelin-producing oligodendrocytes, can promote remyelination in the brain. Using a structural mimetic of its native ligand, BDNF, we show that stimulation of TrkB enhances remyelination, increasing oligodendrocyte differentiation, the frequency of myelinated axons and thickness of the myelin sheath following a demyelinating insult. Further, we show that these effects are dependent on the phosphorylation of oligodendrocyte expressed TrkB receptors in vivo Overall, we demonstrate that selective targeting of TrkB has therapeutic potential to promote remyelination in the brain.

Keywords: BDNF; CNS; TrkB; neurotrophins; oligodendrocytes; remyelination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / drug effects*
  • Brain / metabolism
  • Brain / pathology
  • Brain-Derived Neurotrophic Factor / pharmacology
  • Brain-Derived Neurotrophic Factor / therapeutic use*
  • Cell Division / drug effects
  • Corpus Callosum / metabolism
  • Corpus Callosum / pathology
  • Cuprizone / toxicity
  • Demyelinating Diseases / chemically induced
  • Demyelinating Diseases / drug therapy*
  • Demyelinating Diseases / pathology
  • Female
  • Infusion Pumps, Implantable
  • Infusions, Intraventricular
  • Male
  • Membrane Glycoproteins / agonists*
  • Membrane Glycoproteins / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Molecular Targeted Therapy*
  • Myelin Basic Protein / biosynthesis
  • Myelin Sheath / metabolism*
  • Neural Stem Cells / drug effects
  • Oligodendroglia / drug effects*
  • Peptides, Cyclic / pharmacology
  • Peptides, Cyclic / therapeutic use
  • Phosphorylation
  • Protein Processing, Post-Translational / drug effects
  • Protein-Tyrosine Kinases / metabolism
  • Remyelination / drug effects*
  • Specific Pathogen-Free Organisms

Substances

  • Brain-Derived Neurotrophic Factor
  • Membrane Glycoproteins
  • Myelin Basic Protein
  • Peptides, Cyclic
  • tricyclic-dimeric-peptide-6
  • Cuprizone
  • Ntrk2 protein, mouse
  • Protein-Tyrosine Kinases